PropertyValue
?:abstract
  • The article Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.
?:creator
?:doi
  • 10.1007/s11523-020-00761-7
?:doi
?:journal
  • Targeted_oncology
?:license
  • cc-by-nc
?:pmid
?:pmid
  • 33079308
?:publication_isRelatedTo_Disease
?:source
  • Medline
?:title
  • Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.
?:type
?:year
  • 2020-10-20

Metadata

Anon_0  
expand all